3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Carboplatin
44
Paclitaxel
43
liposomal doxorubicin
23
Topotecan
19
Gemcitabine
18
pembrolizumab
17
Cyclophosphamide
17
Bevacizumab
16
Cisplatin
12
niraparib
9
olaparib
8
fludarabine
7
Taxes
7
Docetaxel
7
aldesleukin
6
Nivolumab
6
Doxorubicin
6
1-dodecylpyridoxal
6
oregovomab
5
fludarabine phosphate
5
Peripheral Blood Stem Cell Transplantation
5
Filgrastim
5
rucaparib
4
durvalumab
4
avelumab
4
Surgical Procedures, Operative
4
Melphalan
4
Ipilimumab
4
Interleukin-2
4
Etoposide
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Ovarian Neoplasms
×
High-Intensity Focused Ultrasound Ablation
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled